Xcell Therapeutics
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Xcell Therapeutics makes cell culture media, the nutrient solutions that keep living cells alive and growing, used in the development and manufacture of cell and gene therapies, a class of advanced biologic medicines.
Its products supply biotech and pharmaceutical companies working on cell therapy, gene therapy, and gene-modified cell therapy. Listed on KOSDAQ, Korea's tech-focused small-cap board, the company is expanding its media portfolio beyond therapeutic use into cultivated-meat ingredients and functional cosmetic raw materials.
Summary is AI-generated and may contain errors · figures from DART filings
The filing notes that most cell culture media used in Korea is currently imported, and Xcell Therapeutics has focused on domestic development of this material since its founding.
Xcell Therapeutics in five facts
What does Xcell Therapeutics do?
Xcell Therapeutics makes cell culture media, the nutrient solutions that keep living cells alive and growing, used in the development and manufacture of cell and gene therapies, a class of advanced biologic medicines.
Where is Xcell Therapeutics listed and in which sector?
Xcell Therapeutics (Korean name: 엑셀세라퓨틱스) trades under KRX code 373110 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Xcell Therapeutics?
Its market capitalisation was US$13.7M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Xcell Therapeutics's latest annual revenue and operating profit?
For fiscal year 2025, Xcell Therapeutics reported revenue of US$1.5M, an operating loss of US$8.2M and a net loss of US$8.2M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 0.8% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Other market noticeOct 12
- Appointment/dismissal/resignation of an independent directorSep 11
- Operating results (consolidated) (preliminary) (fair disclosure)
Xcell Therapeutics filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$1.37M (+778% year on year), an operating loss of US$1.89M and a net loss of US$1.97M.
Earnings · Aug 6 - Completion report on merger, etc. (asset transfer)M&A · Mar 5